呈诺再生医学科技

Chengno Regenerative Medicine is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of induced pluripotent stem cell (iPSC) derived therapies. The company leverages its proprietary iPSC platform to create standardized, off-the-shelf cell products for a variety of high-unmet-need conditions, including ischemic stroke, cardiovascular diseases, and oncology. Its lead candidate, CIN-001, is an iPSC-derived endothelial progenitor cell therapy that has entered clinical trials for the treatment of acute ischemic stroke, representing a milestone in the Chinese regenerative medicine landscape. Chengno aims to revolutionize the field by providing scalable and cost-effective cell-based treatments through its integrated R&D and GMP manufacturing capabilities. The company is supported by prominent investors and maintains strong academic ties to advance its diverse pipeline of regenerative therapies.